Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV, the new coronavirus originating in Wuhan, China. To date, the virus has caused 81 deaths and over 2,800 known infections and is rapidly expanding in various countries.
for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.
Harnessing the Immune System to fight cancer.